In Vitro and in Vivo Properties of Bicyclic Lactam Inhibitors

Leblond, Lorraine; Grouix, Brigitte; Boudreau, Chantal; Yang, Qingshan; Siddiqui, M. Arshad; Winocour, Peter D.

doi:10.1016/s0049-3848(00)00333-9

Cited by 8 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, most of the more potent compounds showed only poor bioavailability, like 73 (K i = 0.6 nM), 74 (K i = 5.5 nM) or 75 (K i = 0.57 nM) all developed by Corvas [112,113]. Shire Biochem introduced the same bicyclic template, which they had already used in their ketone based inhibitor series, like 76 (K i = 7 nM), 77 (K i = 10 nM) and 78 (K i = 1.2 nM) [114][115][116]. Some of the inhibitors have the potential to be promising intravenous antithrombotic agents, but none of them was orally available.…”

mentioning

confidence: 99%

Progress in the Development of Synthetic Thrombin Inhibitors as New Orally Active Anticoagulants

Steinmetzer

Stürzebecher²

2004

CMC

View full text Add to dashboard Cite

The trypsin-like serine protease thrombin is a multifunctional key enzyme at the final step of the coagulation cascade and is involved in the regulation of hemostasis and thrombosis. An increased activation of coagulation can result in severe thromboembolic disorders, one of the major reasons responsible for mortality and morbidity in western world. Therefore, an effective, safe, and orally available thrombin inhibitor could be a useful anticoagulant drug for the daily prophylaxis of venous and arterial thrombosis and prevention of myocardial infarction for high-risk patients. Synthetic thrombin inhibitors have a long history; initial compounds were derived from electrophilic ketone- and aldehyde-analogs of arginine. First potent leads of non-covalent inhibitors were developed in the early eighties, which were further optimised in the nineties, after the X-ray structure of thrombin became available. In the meantime a huge number of highly active and selective inhibitors has been published, however, only a few of them have an appropriate pharmacokinetic and pharmacodynamic overall profile, which could justify their further development. Very recently, with Ximelagatran a first orally available thrombin inhibitor has been approved in France for the prevention of venous thromboembolic events in major orthopaedic surgery after successful clinical phase III. However, it still has to be awaited, whether the extensive clinical use of Ximelagatran can demonstrate for the first time that direct thrombin inhibitors offer a real benefit in terms of efficacy and safety over established antithrombotic therapies. This review summarizes the current status of synthetic thrombin inhibitors with a focus on more recently published and promising new compounds.

show abstract

mentioning

confidence: 99%